2025-06-12-Jefferies-吉利德科学（GILD）_幻灯片_我们的暴露前预防（PrEP）交换者模型表明_LEN在年底前有4_-_5_的交换可行性_72页_2mb

Gilead Sciences (GILD) Equity Research (June 12, 2025)

Analyst Rating: BUY
Price Target: $109.30
12M Upside: +19%
Consensus 2025 Revenue Estimate: $287.2M

Key Analysis Points

1. FDA Approval & PDUFA Deadline:

   • June 19 PDUFA date for HIV PrEP (Lenacapavir). Analysts are confident in approval given high clinical efficacy and regulatory momentum.
   • A clean approval is expected, with a potential stock boost from a strong launch.

2. Market Opportunity:

   • Consensus Revenue 2025: ~$150M for PrEP + $50-60M for HIV treatment (Sunlenca), totaling ~$200M.
   • Long-term Potential: $5B peak revenue by 2032, with $4-5B TAM for PrEP alone.
   • Switch Model: 4-5% patient switch from oral PrEP (e.g., Descovy, Truvada) by YE 2025 could achieve ~$150M in PrEP revenue.

3. Sales Projections:

   • 2026 Revenue: $700M under aggressive swap scenarios (16% swap rate by YE 2026).
   • Peak Revenue: $4-5B by 2030-2032, driven by market growth and expansion into non-PrEP populations.

4. Patient Adoption:

   • Surveys: 95% of patients currently on PrEP expressed willingness to switch to Lenacapavir due to its Q6M injection convenience.
   • Demographics: 96% of patients surveyed were male (average age 30-39), but commercial insurance penetration is high.

5. Commercial Factors:

   • Access Predictions: 75% unrestricted access by 6 months, 90% by 12 months.
   • Reimbursement: Positive development with $0 co-pay eligibility discussions post-commercial agreements.
   • Competition: Descovy is cannibalizing oral PrEP sales, but its growth supports market expansion.

6. Valuation & Risk:

   • Fair Value: $130 PT based on 13x 2026 EPS ($10 EPS) and 19x 2025 EPS.
   • Risks:
     • Headline Risks: Supreme Court ruling on mandatory PrEP coverage (June 2025 deadline).
     • Medicaid Cuts: 10-11% reduction could impact revenues by 2.5% and EPS by 6-8%.
     • Biotech Volatility: Sensitivity to FDA uncertainty and pipeline disappointments.

7. Long-term Thesis:

   • HIV franchise valued at $90-115M via DCF, with potential $5B revenue from long-acting PrEP if 50% market share captured.

Summary

GILEAD'S HIV PrEP (Lenacapavir) faces a critical FDA decision in June 2025. Analysts project strong market uptake (4-5% swap by YE 2025) for PrEP, driving revenue to ~$150M this year and exceeding $700M by 2026. Positive patient surveys and favorable reimbursement trends support an upside scenario that justifies the BUY rating and $130 PT. The outcome depends on FDA approval, regulatory access, and navigating political risks, but the clinical and commercial upside appears significant.